DaVita Inc. $DVA Shares Sold by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC lowered its holdings in shares of DaVita Inc. (NYSE:DVA) by 22.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 186,227 shares of the company’s stock after selling 55,101 shares during the period. Wedge Capital Management L L P NC owned about 0.29% of DaVita worth $41,432,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of DVA. Root Financial Partners LLC raised its holdings in shares of DaVita by 128.0% in the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after acquiring an additional 105 shares during the last quarter. Caitlin John LLC purchased a new stake in DaVita during the 4th quarter worth about $34,000. Sankala Group LLC purchased a new stake in DaVita during the 4th quarter worth about $39,000. Canada Pension Plan Investment Board acquired a new position in DaVita in the 2nd quarter valued at about $43,000. Finally, Kestra Advisory Services LLC purchased a new position in DaVita in the 4th quarter valued at about $45,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DVA has been the topic of several recent analyst reports. Truist Financial reduced their target price on DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a research report on Friday, August 7th. TD Cowen raised shares of DaVita from a “hold” rating to a “buy” rating and upped their price objective for the company from $201.00 to $220.00 in a research note on Friday. Oppenheimer set a $220.00 price objective on DaVita in a report on Friday. Raymond James Financial set a $220.00 target price on shares of DaVita in a report on Friday. Finally, Barclays raised their price objective on DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 5th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $221.75.

Insider Activity at DaVita

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares of the company’s stock, valued at $22,756,029.60. This trade represents a 12.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 1.90% of the company’s stock.

DaVita Price Performance

Shares of DVA stock opened at $178.25 on Wednesday. The company’s fifty day moving average price is $218.11 and its two-hundred day moving average price is $178.10. The firm has a market capitalization of $11.37 billion, a P/E ratio of 14.59, a P/E/G ratio of 0.61 and a beta of 0.88. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $247.49.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, topping analysts’ consensus estimates of $3.88 by $0.14. The firm had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The firm’s revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the business earned $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, sell-side analysts anticipate that DaVita Inc. will post 14.57 EPS for the current year.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.